


October 22, 2021 | Issue 194

Editor's note

This note is produced every Friday by the KPMG Center for Healthcare Regulatory Insight and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to subscribe to our mailing list here.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> here to me, Larry Kocot, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.



Special Supplement: COVID-19 News

In light of the continuing daily volume of COVID-19 activity and news, we have summarized COVID-19 news for the week in this special supplement.





Healthcare regulatory news

CMMI released a strategic plan with a goal to place all Medicare feefor-service beneficiaries and most Medicaid beneficiaries in accountable care arrangements by 2030... CMS launched a webpage to support sharing of state actions to expand Medicaid home and community-based services. HHS <u>proposed withdrawing two Trump Administration rules</u> that restricted government enforcement of <u>agency guidance</u>.

FDA approved <u>Boehringer Ingelheim's Cyltezo</u> as the first <u>interchangeable biosimilar to Humira</u> and Genentech's <u>Tecentriq as an adjuvant treatment</u> for non-small cell lung cancer... FDA <u>proposed establishing</u> an over-the-counter hearing aid market in the US... FDA approved <u>29 priority abbreviated new drug applications in FY21, up from 28 in FY20</u>; approved generics increased from 35 to 53... FDA issued <u>draft guidance for submitting real-world data</u> to support approval applications.

OIG reported <u>UnitedHealthcare received \$3.7B in 2017 MA payments</u> from diagnoses reported only on chart reviews and health-risk assessments.





Healthcare law and policy news

President Biden directed Congressional Democrats to cut the reconciliation package to \$1.75-\$1.9T... Congressional leaders are considering vouchers for Medicare dental benefits and Medicare Advantage cuts to reduce costs... CBO estimated major provisions of the bill, not including new Medicare benefits, would expand coverage to 4.1M people across Medicaid and individual market, while costing \$553.2B over the next decade.

Intelerad Medical Systems <u>acquired Ambra Health</u>... Everly Health <u>acquired Natalist</u>... Oak Street Health <u>acquired RubiconMD</u> (\$130M)... Jefferson Health <u>will partner with General Catalyst</u> to access tools aimed at digital transformation... Takeda Pharmaceuticals and 32PointHealth <u>reached an agreement</u> to offer <u>a significant rebate</u> for a lung cancer drug if it proves ineffective... UnitedHealthcare <u>launched a virtual-first health plan built primarily around telemedicine</u>-based gatekeeping.

JAMA studies found that <u>using a blood pressure monitor paired with a smartphone-based</u> self-management program was associated with lowering blood pressure in 85.7% of adults with stage 2 hypertension; and that <u>parent training in behavior management (PTBM)</u> is an underutilized treatment option for preschoolers with ADHD... A Commonwealth Fund analysis found <u>Medicare Advantage and fee-forservice beneficiaries (excluding SNP enrollees) report similar</u> health care experiences.

American Academy of Pediatrics, American Academy of Child and Adolescent Psychiatry, and Children's Hospital Association <u>released a joint statement declaring a national mental health crisis</u> among children and teenagers.





Questions or comments, please send to <u>ushcinsight@kpmg.com</u>.

Succeeding in the new reality

Visit the COVID-19 resource center for KPMG analysis, insights, and perspectives.



kpmg.com/socialmedia











Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please click here. If you wish to unsubscribe from all KPMG communications, please click here.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2021 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP131714-1A

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.



COVID-19 by the Numbers

There have now been <u>roughly 45.3 million confirmed COVID-19 cases</u> in the US, with a death toll over 730,000... The country is <u>averaging nearly 80,000 new cases per day</u> over the past week, down 22% over the past two weeks; deaths per day are down 14% to roughly 1,600... A <u>CDC analysis found that 93%</u> of COVID-19 hospitalizations among children and adolescents June to September occurred among the unvaccinated... CDC data show that even vaccinated Americans who are <u>80+ years old are at higher risk of dying</u> from COVID-19 than anyone under the age of 50, vaccinated or not.

411 million COVID-19 <u>vaccine doses have been administered</u> in the US (roughly 834,000/day over the past week)... Nearly 220 million Americans (<u>77.4% of Americans 12 and older</u>) have received at least one COVID-19 vaccine dose; nearly 190 million Americans are fully vaccinated (66.9% of Americans 12 and older); 11.6 million Americans have received a booster dose.

World Health Organization (WHO) said that <u>only two in five healthcare workers are fully vaccinated</u> across the globe and roughly 115,000 healthcare workers died from COVID-19 from January 2020 to May 2021.

Executive and Administrative Action

The White House on Wednesday <u>outlined its plan to distribute doses</u> of Pfizer-BioNTech's Covid-19 vaccine to kids ages 5 to 11 as soon as its authorized by U.S. drug regulators; the administration has secured enough vaccine for all 28 million 5- to 11-year-olds and will distribute these in smaller dosing and with smaller needles.

The US has <u>now donated and delivered 200 million doses of COVID-19 vaccines</u> to more than 100 countries around the world.

The US will <u>open its borders to vaccinated foreign</u> travelers, including those with a combination of FDA or WHO-authorized vaccines, on November 8.

HRSA plans to <u>continue collecting information from Provider Relief Fund recipients</u> even after the public health emergency ends to ensure compliance with statutory and programmatic requirements.

Healthcare Law, Business, and Policy News

A <u>JAMA</u> study found that 4.6% of privately insured patients had mean out-of-pocket costs of \$3,840 for COVID-related hospitalizations.

UnitedHealth will repay providers who were underpaid for administering COVID-19 vaccines.

Surveillance, Testing, and Treatment

FDA <u>authorized the use of COVID-19 vaccine boosters from Moderna and Johnson & Johnson</u> and cleared the use of "mix-and-match" vaccine regimens (i.e., allowing individuals to receive a booster shot of a different COVID-19 vaccine than the one they originally received)... The authorization followed the Vaccines and Related Biological Products Advisory Committee unanimously recommending that anyone who <u>received a Johnson & Johnson COVID-19 be offered a second dose</u> and that a <u>subset of individuals who received the Moderna vaccine</u> be given boosters... the CDC Advisory Committee on Immunization Practices followed suit and <u>unanimously recommended booster doses</u> of Moderna's COVID-19 vaccine for people 65 and older and other adults at high risk of severe COVID-19 because of health conditions or their employment who received their first dose at least six months ago and of J&J's COVID-19 vaccine for all individuals 18 and older who received a first dose at least two months ago.

A CDC study found that the Pfizer-BioNTech vaccine was <u>93% effective against COVID-19 hospitalization</u> <u>for children ages 12 to 18</u>... Pfizer and BioNTech reported that their booster <u>shot was 95.6% effective</u> against symptomatic COVID-19.

CDC data show that while unvaccinated individuals are more than six times as likely to test positive and more than eleven times more likely to die from COVID-19 than those who are vaccinated, among those vaccinated, individuals receiving a J&J vaccine were most likely to be infected and those receiving Moderna were least likely to be infected.

Valneva reported that its <u>COVID-19 vaccine produced protective antibodies roughly 40 percent higher</u> than the Oxford-AstraZeneca vaccine and prevented infection at a similar rate in a phase 3 clinical trial; the company could seek UK authorization by the end of the year.

WHO's Access to COVID-19 Tools Accelerator is <u>aiming to obtain antiviral drugs for COVID-19 patients</u> with mild symptoms for as little as \$10 per treatment.

The Gates Foundation is <u>committing \$120 million to accelerate production of generic versions</u> of Merck's antiviral pill to increase access in low-income countries.

Altea Pharmaceuticals reported that its <u>COVID-19 antiviral pill failed to combat the virus in a clinical trial</u>, prompting the company to delay follow-on studies.